|
End-of-day quote
Shanghai S.E.
2026-09-04
|
5-day change | 1st Jan Change | ||
| 70.10 CNY | -1.89% |
|
-0.40% | +2.98% |
| 09-04 | Gan & Lee Pharma Gets China Nod for Diabetes, Obesity Drug Trial | MT |
| 09-03 | Gan & Lee Pharmaceuticals And The Menarini Group Enter Exclusive License Agreement For Bofanglutide In Europe | CI |
| Market Cap | 41.72B 6.21B 5.35B 5.03B 4.6B 8.6B 587B 8.62B 59.46B 23.07B 301B 23.34B 22.83B 970B | P/E 2026 * |
30.2x | P/E 2027 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise Value | 38.52B 5.74B 4.94B 4.65B 4.24B 7.94B 542B 7.96B 54.89B 21.3B 278B 21.55B 21.08B 895B | EV / Sales 2026 * |
8.15x | EV / Sales 2027 * | 6.77x |
| Free-Float |
57.83% | Yield 2026 * |
0.34% | Yield 2027 * | 0.39% |
| 1 day | -1.89% | ||
| 1 week | -0.40% | ||
| Current month | +1.70% | ||
| 1 month | +0.14% | ||
| 3 months | +30.52% | ||
| 6 months | +12.96% | ||
| Current year | +2.98% |
| 1 week | 67.98 |  | 71.91 |
| 1 month | 65 | | 79.99 |
| Current year | 51.51 | | 79.99 |
| 1 year | 51.51 | | 82.25 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 83.38 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 2025-05-29 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 2026-03-08 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Fu Ming Xu
BRD | Director/Board Member | 41 | 2025-11-16 |
Zhong Ru Gan
CHM | Chairman | 78 | 1998-06-16 |
Kai Du
BRD | Director/Board Member | 49 | 2009-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.89% | -0.40% | -2.04% | +66.11% | 6.21B | |
| -1.87% | +4.22% | +45.93% | -0.47% | 82.65B | |
| -0.57% | +1.27% | -17.24% | -34.99% | 60.24B | |
| -2.23% | +5.48% | +499.46% | +29.31% | 58.11B | |
| -2.03% | -2.62% | -7.46% | +27.87% | 49.68B | |
| -4.58% | -2.73% | +2.93% | +157.71% | 46.66B | |
| -1.64% | +1.07% | +57.80% | -17.34% | 32.63B | |
| -0.98% | +1.91% | +48.35% | +95.93% | 25.69B | |
| -0.19% | -4.74% | +2.30% | +196.81% | 22.73B | |
| -1.13% | -2.45% | +65.99% | +110.75% | 16.51B | |
| Average | -1.58% | -0.04% | +69.60% | +63.17% | 40.11B | |
| Weighted average by Cap. | -1.68% | +0.76% | +89.26% | +42.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.73B 704M 606M 570M 521M 974M 66.47B 977M 6.74B 2.61B 34.1B 2.64B 2.59B 110B | 5.53B 824M 709M 667M 609M 1.14B 77.81B 1.14B 7.88B 3.06B 39.92B 3.09B 3.03B 129B |
| Net income | 1.39B 207M 178M 168M 153M 286M 19.54B 287M 1.98B 768M 10.02B 777M 760M 32.29B | 1.6B 238M 205M 193M 176M 330M 22.49B 330M 2.28B 884M 11.54B 894M 875M 37.17B |
| Net Debt | -3.2B -477M -411M -386M -353M -660M -45.04B -662M -4.56B -1.77B -23.11B -1.79B -1.75B -74.45B | -4.28B -637M -548M -516M -471M -881M -60.15B -884M -6.09B -2.37B -30.86B -2.39B -2.34B -99.42B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | CN¥70.10 | -1.89% | 6,209,819 |
| 26-09-03 | CN¥71.45 | +2.66% | 7,840,579 |
| 26-09-02 | CN¥69.60 | -2.07% | 6,927,460 |
| 26-09-01 | CN¥71.07 | +3.10% | 9,286,600 |
| 26-08-31 | CN¥68.93 | -2.06% | 6,836,729 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
